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The reinforcing and psychomotor effects of morphine involve opiate stimulation of the dopaminergic system via activation of -opioid
receptors (OR). Both -opioid and dopamine receptors are members of the G-protein-coupled receptor (GPCR) family of proteins.
GPCRs are known to undergo desensitization involving phosphorylation of the receptor and the subsequent binding of arrestins, which
prevents further receptor–G-protein coupling. Mice lacking arrestin-2 (arr2) display enhanced sensitivity to morphine in tests of pain
perception attributable to impaired desensitization of OR. However, whether abrogating OR desensitization affects the reinforcing
and psychomotor properties of morphine has remained unexplored. In the present study, we examined this question by assessing the
effects of morphine and cocaine on locomotor activity, behavioral sensitization, conditioned place preference, and striatal dopamine
release in arr2 knock-out (arr2-KO) mice and their wild-type (WT) controls. Cocaine treatment resulted in very similar neurochemical
and behavioral responses between the genotypes. However, in the arr2-KO mice, morphine induced more pronounced increases in
striatal extracellular dopamine than in WT mice. Moreover, the rewarding properties of morphine in the conditioned place preference
test were greater in the arr2-KO mice when compared with the WT mice. Thus, arr2 appears to play a more important role in the
dopaminergic effects mediated by morphine than those induced by cocaine.
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Introduction
Morphine (Mor) has been used for centuries to alleviate pain;
however, its use is limited by a number of adverse consequences,
including constipation, respiratory suppression, and the poten-
tial development of dependence and addiction after extended
periods of administration. The physiological actions of morphine
are recognized to be mediated principally through the -opioid
receptor (OR). This concept, which is suggested by extensive
pharmacological experiments, has been greatly strengthened by
the finding that mice lacking the OR do not experience
morphine-mediated antinociception, respiratory suppression,
inhibition of gastrointestinal transit, or increased locomotor ac-
tivity (Matthes et al., 1996; Sora et al., 1997; Kieffer, 1999). More-
over, mice lacking the OR do not show a preference for mor-
phine over vehicle in studies designed to test drug reinforcement
(Matthes et al., 1996; Kieffer, 1999), supporting the pharmaco-
logical inhibitor studies demonstrating the importance of the
OR in self-administration paradigms (Mello and Negus, 1996).
Therefore, the disruption of OR regulation could potentially
alter the behavioral effects of morphine.
As with other members of the G-protein-coupled receptor
(GPCR) superfamily, the OR is subject to regulation by phos-
phorylation and subsequent interactions with arrestins. This
process has been shown to be an important step in receptor de-
sensitization (Ferguson et al., 1998; Lefkowitz, 1998; Zhang et al.,
1998; Perry and Lefkowitz, 2002). When the arrestin-2 (arr2)
gene is inactivated in mice by genetic deletion, the antinocicep-
tive effects of morphine are enhanced and prolonged (Bohn et al.,
1999, 2002). The antinociceptive behaviors are correlated with
enhanced OR–G-protein coupling, suggesting that the arr2
molecule acutely regulates the signaling potential of the receptor
(Bohn et al., 1999, 2002). Furthermore, tolerance to the antino-
ciceptive effects of morphine is attenuated in arr2 knock-out
KO mice (arr2-KO) (Bohn et al., 2000). Together, these studies
demonstrate that, by eliminating the arr2 regulatory molecule,
the desensitization of the OR is impaired, leading to dramati-
cally attenuated antinociceptive tolerance.
Alternatively, when the same mice that do not develop mor-
phine tolerance were tested for opiate dependence, they displayed
physical withdrawal symptoms to the same extent during acute
naltrexone treatment, revealing that, although the arr2-KO
mice did not experience antinociceptive tolerance to morphine,
they still became physically dependent on the drug (Bohn et al.,
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2000). These findings suggest that the means of regulating the
OR may vary in different systems, with arr2 playing an impor-
tant role in morphine antinociceptive tolerance but not necessar-
ily in the development of opiate dependence. Therefore, it is in-
teresting to determine whether the arr2-KO mice reveal
differences in other behavioral effects of morphine, particularly
those associated with drug reinforcement.
Although the action of morphine on brain circuitry related to
reward mechanisms is complex, the substantial contribution of
the mesolimbic dopamine (DA) system is well recognized (Di
Chiara and Imperato, 1988; Wise and Rompre 1989; White and
Kalivas, 1998; De Vries and Shippenberg, 2002). For instance,
mice lacking the D2 dopamine receptor do not present
morphine-induced locomotor activity, conditioned place prefer-
ence, and self-administration (Maldonado et al., 1997; Elmer et
al., 2002). Morphine and dopamine bind to their respective
GPCRs to mediate their physiological responses. Because arr2
has been shown to regulate dopamine receptors in vitro (Kim et
al., 2001) as well as opioid receptors both in vitro and in vivo
(Whistler and von Zastrow, 1998; Zhang et al., 1998; Bohn et al.,
1999; Oakley et al., 2000), the loss of this regulatory component
could potentially impact the opioid and/or dopamine system di-
rectly. In an attempt to pharmacologically dissect these two
GPCR signaling systems (opioid and dopamine), cocaine (COC)
(which exerts its action in part as an indirect agonist of the dopa-
mine receptors) and morphine were used in parallel. By measur-
ing both neurochemical and behavioral parameters of the dopa-
minergic system, we asked whether differences between the wild-
type (WT) and arr2-KO mice could be seen with either drug.
Materials and Methods
Animals and drugs
WT, heterozygous (HT), and KO mice were generated as littermates by
crossing heterozygous arr2 C57BL/6  129SvJ mice (which has now
been maintained over nine generations) as initially described (Bohn et
al., 1999). Mice used in this study were age-matched, 3- to 5-month-old
male siblings weighing between 20 and 35 gm, and genotype was deter-
mined by PCR analysis of DNA extracted from ear punch tissue. In all
experiments, WT littermates served as controls for the arr2-HT and
arr2-KO mice, and all genotypes were evaluated simultaneously. Before
the experiment, all mice are provided food and water ad libitum. Mice
were only used once in each experiment as indicated; a new group of mice
was used for each dose and drug tested. Experiments were conducted in
accordance with the National Institutes of Health guidelines for the care
and use of animals and with an approved animal protocol from the Duke
University Animal Care and Use Committee. Morphine sulfate and co-
caine were purchased from Sigma-RBI (St. Louis, MO) and freshly pre-
pared in saline (Sal). All compounds were injected at a volume of 10
l/gm animal weight as specified.
Locomotor activity
Activity was measured in an Omnitech Digiscan activity monitor (20 
20 cm 2; Accuscan Instruments, Columbus, OH). Locomotor activity was
measured at 5 min intervals, and cumulative counts were taken for data
analysis; data were analyzed for the total number of beam breaks seen in
5 min increments, a measure that assesses all movements, including run-
ning and turning behaviors (Wang et al., 1997; Xu et al., 2000). To eval-
uate the effects of morphine or cocaine on locomotor behavior, mice
were placed in activity monitor for a 60 min habituation period. Imme-
diately after the 60 min habituation period, mice were injected with drug
or saline and placed back into the monitor, and locomotor activity was
recorded for the following 120 min. In all acute experiments, each animal
received only a single injection of each drug. In morphine sensitization
experiments, mice were first exposed to the activity boxes for 30 min, 4 d
before the test. On day 1, mice were habituated to the activity box for 30
min, morphine (10 mg/kg, s.c.) was then given, and activity was recorded
for 2 hr. The same group of mice was administered morphine (10 mg/kg,
s.c.) once per day for the next 6 consecutive days in home cages for a total
of 7 d of chronic daily morphine treatment. On the eighth day, the mice
were not handled or treated. On day 9, the mice were treated the same as
on day 1; after a 30 min habituation, morphine (10 mg/kg, s.c.) was
administered, and activity was monitored for 2 hr. The cocaine sensiti-
zation protocol was performed in a similar manner as morphine. After a
30 min habituation period, mice received cocaine (20 mg/kg, i.p.) on day
1, and locomotor activity was immediately assessed. Mice then received
four additional daily injections of cocaine (20 mg/kg, i.p.) in home cages,
were not handled or treated on the sixth day, and received another dose
of cocaine (20 mg/kg, i.p.) on the seventh day, at which time activity was
again assessed (Wang et al., 1997; Xu et al., 2000).
In vivo microdialysis
Microdialysis was performed as described previously (Wang et al., 1997;
Xu et al., 2000). Anesthetized mice were placed in a stereotaxic frame,
and dialysis probes (2 mm membrane length, 0.24 mm outer diameter,
Cuprophane, 6 kDa cutoff; model CMA-11; CMA Microdialysis, Solna,
Sweden) were implanted into the right striatum. The stereotaxic coordi-
nates for implantation of microdialysis probes were as follows: antero-
posterior, 0.0 mm; dorsoventral, 4.4 mm; lateral, 2.5 mm relative to
bregma (Franklin and Paxinos, 1997). Placement of the probe was veri-
fied by histological examination subsequent to the experiments. After
surgery, animals were returned to their home cages with access to food
and water ad libitum. Twenty-four hours after surgery, the dialysis probe
was connected to a syringe pump and perfused at 1 l/min with artificial
CSF (in mM): 150 Na , 3.0 K , 1.4 Ca 2, 31.0 PO4
, 0.8 Mg2, and 155
Cl  (ESA, Bedford, MA). After a 1 hr equilibration period, the perfusates
were collected every 20 min to a tube containing 2 l of 1 M HClO4. At
least four control samples were taken before drugs were administered
systemically. Dialysates were analyzed for levels of dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA)
using HPLC with electrochemical detection. DA and metabolites were
separated on a microbore reverse-phase column (5 m, 1  150 mm;
model C-18, Unijet; BAS, West Lafayette, IN) with a mobile phase con-
sisting of 0.03 M citrate–phosphate buffer with 2.1 mM octyl sodium
sulfate, 0.1 mM EDTA, 10 mM NaCl, and 17% methanol, pH 3.6, at a flow
rate of 80 l/min and detected by a 6 mm glass carbon electrode (Unijet;
BAS) set at 0.8 V. The volume of injection was 5 l. Under these
conditions, the basal levels of dopamine, DOPAC, and HVA in the dia-
lysates were collected from each genotype before treatment (saline, mor-
phine, or cocaine) and were as follows: (1) dopamine, 52  6.6 fmol/20
l; 68  17 fmol/20 l; (2) DOPAC, 5.9  0.6 pmol/20 l; 7.2  1.2
pmol/20 l; and (3) HVA, 9.3  1.0 pmol/20 l; 9.4  1.0 pmol/20 l for
WT (n  19) and arr2-KO (n  15) mice, respectively.
Conditioned place preference
The commercially designed place preference chambers (model ENV-
3013) for mice were purchased from Med Associates (St. Albans, VT).
Each chamber was housed in a sound-attenuating box, and individual
fans provided ventilation. The chambers consisted of three distinct com-
partments, separated by optional manual guillotine doors and illumi-
nated with a separate light in the laminate top of each compartment. The
location of the mouse was determined by automated data collection
using photobeam strips that recorded the time spent in each of the three
compartments. The experiments were conducted in a designated mouse
testing room in which no other activities took place during the test times.
Each of the three compartments in the place preference chamber was
distinct. The center compartment was 2.85  5  5 inches, with all gray
walls and floor. The two “choice” compartments were 6.6  5  5 inches.
One choice compartment was black with a stainless steel grid rod floor,
and the other compartment was white with a stainless steel mesh floor.
Each compartment also contained a removable, stainless steel waste pan.
A small amount of corncob bedding was added to the waste pan under
the mesh floor of one side, and an intact “Orange Spice” Bigelow tea bag
was included along with the corncob bedding in the waste pan under the
grid floor of the other compartment. The place preference procedure
consisted of three phases: preconditioning, conditioning, and post-
conditioning.
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Preconditioning. During the preconditioning phase of the experiment,
mice were place into the center gray compartment, and the doors be-
tween the black and white compartments were open. The time spent in
each of the compartments was recorded for a 30 min period. If a mouse
spent more than 60% of the 30 min preconditioning period in either the
black or white chamber or more time in the gray chamber than in one of
the choice chambers, it was eliminated from further experimentation.
This resulted in 15–25% elimination in each treatment group. The
conditioning phase commenced the following day.
Conditioning phase. Mice were treated with morphine or cocaine at the
designated doses on days 1, 3, and 5 and saline on days 2, 4, and 6 of the
conditioning phase. Because the initial criteria required that no mice
show a marked preference for either side on the preconditioning day, the
drug was randomly paired with alternating compartments such that, in
any group, half of the mice received drug in the black compartment and
the other half received drug in the white compartment. After drug or
saline administration, mice were placed in the appropriate compart-
ment. Testing occurred on the day after the 6 d conditioning phase.
Postconditioning test. Mice were handled on the test day in the same
manner as on the preconditioning day and received no drug or saline
administrations. With the chamber doors open, the mouse movements
were automatically recorded for a total of 30 min. Data were analyzed for
the first 10, 15, and 20 min of the preconditioning and postconditioning
phases of the experiment by subtracting the time spent in the drug-
assigned chamber in the preconditioning period from the time spent in
that chamber in the postconditioning period.
Statistical analyses
Data presented as responses repeatedly measured over time were ana-
lyzed using a two-way ANOVA for repeated measures using the SAS
statistical software (version 6.11; SAS Institute, Cary, NC). Dose– effect
curves were compared using standard two-way ANOVA, and individual
doses were compared via Bonferroni post hoc analysis (GraphPad Soft-
ware, San Diego, CA). Sensitization data were analyzed by a three-way
ANOVA for repeated measures. Degrees of freedom for corresponding
factor and error are shown for the ANOVA analyses. A Mann–Whitney U
test (two-tailed) was used to compare genotypes in the microdialysis
assays in which the data has been presented in a normalized percentage
basis (Morari et al., 1998). Comparisons of drug effects are made after
drug administration (after habituation periods on locomotor activity
curves).
Results
As an initial screen for potential alterations in dopamine func-
tions, locomotor activity was measured in the arr2-KO mice in
the novel environment of the test chamber. During a 1 hr habit-
uation period, although both genotypes became less active over
time (Fig. 1A) (F(11,1022)  32.89; p  0.0001), the arr2-KO
mice demonstrated significantly less horizontal activity com-
pared with WT mice (Fig. 1A) (F(1,93)  8.26, p  0.005; no
interaction of factors was detected, F(11,1022  0.223, p  0.9952).
A similar trend was also observed when activity was analyzed for
distance traveled or vertical activity (data not shown). Morphine
(10 mg/kg, s.c.) was administered to mice of both genotypes at a
dose that has been shown to increase activity in mice (Oliverio et
al., 1975; Brase et al., 1977; Miner 1997). Morphine produced
marked increases in locomotor activity in all three genotypes
(F(23,483)  27.94; p  0.0001). At this dose, the WT mice appear
to be more activated than the arr2-KO or heterozygotes, al-
though this did not prove to be significantly different (for geno-
type, F(2,21)  2.62, p  0.0965; interaction genotype  time,
F(46,483)  1.70, p  0.01). To further investigate whether there
was a difference in morphine-induced locomotor activity be-
tween genotypes, several doses were tested (Fig. 1C). Increases in
the number of beam breaks (as accumulated during a 120 min
period) after morphine injection were significantly lower in
arr2-KO mice than in their WT counterparts overall (Fig. 1C)
(for genotype, F(1,95)  70.22, p  0.001; for dose, F(4,95)  36.07,
p  0.0001; interaction genotype  dose, F(4,95)  9.49, p 
0.0001). Although it is possible that the lower basal activity of the
arr2-KO mice may contribute to the decreased responsiveness
to morphine, it is unlikely that this alone can completely explain
Figure 1. Locomotor activity after acute morphine treatment. A, Basal locomotor activity in
WT and arr2-KO mice during a 1 hr habituation period (for time, F(11,1022)  32.89, p 
0.0001; for genotype, F(1,93)  8.26, p  0.005; n  46 – 49). B, Effects of an acute dose of
morphine. Morphine (10 mg/kg, s.c.) was administered to wild-type (n  8), heterozygotes
(n  8), and arr2-KO (n  8) mice after a 1 hr habituation period. Locomotor activity was
assessed as the number of infrared beam breaks in 5 min intervals. The values were averaged
across mice, and the means  SEM are shown here. Morphine-induced locomotor activity in all
three groups, yet the genotypes did not differ significantly at this dose (for genotype,
F(23,483)  27.94, p  0.0001; for dose, F(2,21)  2.62, p  0.0965). C, Morphine dose–
response curve for locomotor activity. The number of beam breaks was summed over the 120
min test period, and the mean  SEM after morphine or saline (10 l/g, s.c.) administration is
presented. The sum of the beam breaks in B is included in this graph, representing the 10 mg/kg
dose. Overall, morphine produced greater increases in locomotor activity in WT mice than in the
arr2-KO mice (for genotype, F(1,95) 70.22, p0.001; for dose, F(4,95) 36.07, p0.0001;
n  8 –16). Bonferroni post hoc analysis revealed significant differences between the geno-
types at the doses of 5, 20, and 40 mg/kg subcutaneous morphine (WT vs KO; *p  0.05;
**p  0.001).
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the extent of the differences in activity after morphine adminis-
tration measured in these mice. This observation was surprising
in the context of our previous studies in which morphine pro-
duced a greater degree of antinociception in arr2-KO mice than
in their WT littermate controls because, in the locomotor activity
test, the degree of activation is actually less in the knock-out mice.
At the same time, a moderate dose of cocaine (20 mg/kg, i.p.)
produced similar profiles of locomotor activation in both geno-
types (Fig. 2A) (for genotype, F(1,23)  0.96, p  0.3371; for time,
F(17,391)  12.40, p  0.0001; interaction genotype  time,
F(17,391)  0.15, p  1.0000). Although the arr2-KO mice appear
to be slightly less activated by cocaine than their WT littermates
in Figure 2A, this profile of activity closely resembles that seen in
the basal state (Fig. 1A) in which the arr2-KO mice are generally
less active. In the dose–response curve, both genotypes displayed
similar response profiles to different doses (10, 20, and 30 mg/kg,
i.p.) of cocaine tested (Fig. 2B) (for genotype, F(1,62)  0.08, p 
0.7723; for dose, F(3,62)  22.88, p  0.0001; interaction geno-
type  dose: F(3,62)  0.37, p  0.7738). Together, these data
indicate that morphine produces markedly differential effects on
locomotor activity in the knock-out versus WT mice, although
no such obvious differences were observed with cocaine.
Locomotor activation can be further enhanced after chronic
administration of the drug in a process known as locomotor sen-
sitization or “reverse tolerance” (White and Kalivas, 1998; Rob-
inson and Berridge, 2000; De Vries and Shippenberg, 2002). Al-
though the increases in acute locomotor activity are believed to
be a result of increased extracellular dopamine levels, sensitiza-
tion appears to predominantly involve enhanced sensitivity of
dopamine receptor signaling but may also involve alterations in
the control of extracellular dopamine dynamics (Koob and Nes-
tler 1997; White and Kalivas, 1998; Chefer and Shippenberg,
2002). This phenomenon is believed to be reflective of long-term
cellular plasticity associated with drug addiction (Nestler, 2001).
The effects of morphine and cocaine in behavioral sensitization
paradigms were assessed. Because the mice were habituated after
30 min (Fig. 1A) and the morphine effect was most prominent in
the first 90 min (Fig. 1B), the duration of these test times were
shortened accordingly in the sensitization experiment to decrease
the overall time spent in the activity box because repeated mea-
surements were to be made on different days. After 6 d of chronic
morphine treatment, both genotypes reveal an enhanced increase
in locomotor activity compared with their response on the first
day of treatment, indicating that both genotypes become sensi-
tized to repeated morphine treatment, and the degree of sensiti-
zation was similar in both genotypes (Fig. 3) (for sensitization,
F(1,36)  5.68, p  0.05; for genotype, F(1,36)  3.78, p  0.06;
interaction genotype  sensitization, F(1,36)  0.08, p  0.7766).
In the cocaine sensitization experiment, both genotypes also re-
veal greater locomotor activity after the repeated administrations
of cocaine, yet no difference between the genotypes was deter-
mined (Fig. 4) (for sensitization, F(1,39)  7.67, p  0.01; for
genotype, F(1,39)  0.00, p  0.9474; interaction genotype 
sensitization, F(1,39)  0.02, p  0.8811).
The acute administration of morphine and cocaine increases
the extracellular levels of dopamine in several brain regions (Di
Chiara and Imperato, 1988; Pontieri et al., 1995; Rocha et al.,
1998; He and Shippenberg, 2000). Extracellular levels of dopa-
mine can be directly measured by in vivo microdialysis in which a
Figure 2. Locomotor activity after acute cocaine treatment. A, Cocaine (20 mg/kg, i.p.) was
administered to WT (n  15) and arr2-KO (n  12) mice after a 1 hr habituation period.
Locomotor activity was assessed as described in Figure 1. Although cocaine produced marked
increases in locomotor activity in both genotypes, WT mice displayed slightly higher activity
than the arr2-KO mice after morphine (for time, F(17,391)  12.40, p  0.0001; for genotype,
F(1,23)  0.96, p  0.3371). B, Dose–response curve for cocaine-induced locomotor activity.
Data represent the sum of the activity after each dose over a 90 min period. There were no
significant differences between the genotypes (F(1,62)  0.08; p  0.7723; n  7–15).
Figure 3. Locomotor sensitization to morphine. Locomotor activity was initially assessed in
WT and arr2-KO mice during a 30 min habituation period and for 90 min after an acute dose of
morphine (10 mg/kg, s.c.). After this observation, mice received one daily dose of morphine (10
mg/kg, s.c.) for 6 additional days in their home cage. After 1 d of rest, the mice were then
challenged again with the same dose of morphine (10 mg/kg, s.c.), and locomotor activity was
assessed (WT-S, arr2-KO-S). Locomotor activity was increased significantly after this regimen
in both WT and arr2-KO mice, indicating that sensitization to morphine developed in both
genotypes (for sensitization, F(1,36)  5.68, p  0.05; for genotype, F(1,36)  3.78, p  0.06;
n  10 of each genotype.)
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probe is inserted into the striatum to allow collection of samples
in a conscious, freely moving mouse (Wang et al., 1997; Gainet-
dinov et al., 1999b; Chefer and Shippenberg, 2002). Here, striatal
microdialysis was performed to see whether the rise in extracel-
lular dopamine is comparable between the arr2-KO and WT
mice after drug treatment. Samples were collected from the stri-
atum of freely moving mice and assessed for dopamine, and its
metabolites DOPAC and HVA, by HPLC after either saline or
morphine (10 mg/kg, s.c.) treatment (Fig. 5). As might be ex-
pected, morphine induced a significant increase in extracellular
dopamine and metabolite levels in both genotypes (Fig. 5) (WT
plus Sal vs WT plus Mor: dopamine, DOPAC, and HVA, p 
0.01; arr2-KO plus Sal vs arr2-KO plus Mor: dopamine,
DOPAC, and HVA, p  0.01; two-tailed Mann–Whitney U test).
Surprisingly, significantly more dopamine was released, particu-
larly in the first hour of treatment after morphine, in the
arr2-KO mice than in the WT littermates (Fig. 5) ( p  0.05;
two-tailed Mann–Whitney U test). This effect was also seen in the
measurements of the dopamine metabolites DOPAC and HVA,
indirect indicators of increased dopaminergic neuron function
(Fig. 5) (WT vs arr2-KO; p  0.01; two-tailed Mann–Whitney
U test). Saline treatment did not reveal differences in dopamine
or metabolite levels between the genotypes, nor did the basal
levels vary (see Materials and Methods) (Fig. 5).
Cocaine-induced elevation in extracellular dopamine was also
assessed by in vivo microdialysis. Cocaine at 20 mg/kg intraperi-
toneally increased extracellular dopamine over saline-treated
controls (WT plus Sal vs WT plus COC, arr2-KO plus Sal vs
arr2-KO plus Mor: p  0.01; two-tailed Mann–Whitney U test).
This degree of stimulation was to the same extent in both the
arr2-KO and WT mice (Fig. 6). The levels of dopamine metab-
olites after cocaine did not differ between genotype or with the
saline-treated controls (data not shown) as is expected for a
transporter blocker (Nomikos et al., 1990). The levels of dopa-
mine after cocaine are similar between the genotypes and corre-
lates well with the similar extent of their locomotor responses to
the drug (Fig. 2).
A conditioned place preference paradigm was used to deter-
mine whether the rewarding or reinforcing properties of mor-
phine or cocaine were affected by elimination of arr2 (Shoaib et
al., 1995; Miner, 1997; Martin et al., 2000). In Figure 7A, the
preference is shown at three different experimental conditions
after 3 mg/kg subcutaneous morphine in which we examined the
change in time spent in the drug-paired compartment, in which
the preconditioning and postconditioning times were set at 10,
15, or 20 min. By examining the data in this way, it demonstrates
that even early (10 min) in the time period of choosing sides, the
arr2-KO mice experienced more preference than the WT mice
for the morphine-paired side (Fig. 7A) (for genotype: F(1,11) 
5.53, p  0.05; for time, F(2,22)  15.20, p  0.0001; interaction
genotype  time, F(2,22)  0.49, p  0.6218). A dose–response
Figure 4. Locomotor sensitization to cocaine. Locomotor activity was initially assessed in WT
and arr2-KO mice during a 30 min habituation period and for 90 min after an acute dose of
cocaine (20 mg/kg, i.p.). Mice then received one daily dose of cocaine (20 mg/kg, i.p.) for 4
additional days in their home cage. After 1 d of rest, the mice were then challenged again with
the same dose of cocaine (20 mg/kg, i.p.), and locomotor activity was again assessed (WT-S,
arr2-KO-S). Data represent the sum of the number of beam breaks recorded during 60 min
after drug administration. Both groups of mice became sensitized to cocaine to a similar extent
(for time, F(1,39)  7.67, p  0.01; for genotype, F(1,39)  0.00, p  0.9474; n  7–14.)
Figure 5. In vivo microdialysis after acute morphine. The effects of morphine (10 mg/kg, s.c.)
and saline (10 l/g, s.c.) on extracellular DA, DOPAC, and HVA levels in the striatum of freely
moving mice as measured using in vivo microdialysis. Data are presented as the percentage of
the average level of dopamine or metabolite measured in at least three samples collected before
the drug administration. Analysis of area under curve values for 3 hr after administration (data
not shown) revealed a significant effect of morphine on extracellular dopamine and metabolites
in both genotypes: WTSal vs WTMor, dopamine, DOPAC, and HVA, p  0.01; arr2-
KOSal vs arr2-KOMor, dopamine, DOPAC, and HVA, p  0.01; Mann–Whitney U test
(two-tailed). Analysis of the 1 hr period after morphine administration (data not shown) re-
vealed that arr2-KO mice produced a greater accumulation of dopamine and metabolites: WT
(n  9) vs arr2-KO (n  6) after morphine, DA, p  0.05; DOPAC and HVA, p  0.01;
Mann–Whitney U test (two-tailed). Similar analysis of saline effects (1 or 3 hr period) revealed
no significant differences between the genotypes (WT, n  5; arr2-KO, n  5; p  0.05;
two-tailed Mann–Whitney U test).
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analysis was also performed, and, at each of the doses of mor-
phine examined (1, 3, and 6 mg/kg, s.c.), the arr2-KO mice
showed a greater preference for the morphine-paired compart-
ment than their WT littermates (Fig. 7B) (for genotype, F(1,41) 
6.31, p  0.05; for dose, F(2,41)  7.05, p  0.01; interaction
genotype  dose, F(2,41)  0.21, p  0.8105). Together, these data
indicate that the rewarding properties of morphine, as measured
in the conditioned place preference procedure, are enhanced in
arr2-KO mice over those observed in the WT controls (Fig. 7)
We also examine the conditioned place preference induced by
cocaine in each genotype. A dose of 10 mg/kg intraperitoneally,
which has been used previously in this type of experiment to
induce preference in normal mice (Zhang et al., 2002), induced
similar levels of preference in both genotypes, and this remained
constant at each of the preconditioning and postconditioning
time points examined (Fig. 8) (for genotype, F(1,16)  0.05, p 
0.8179; for time, F(2,32)  5.95, p  0.01; interaction genotype 
time, F(2,32)  0.34, p  0.01).
Discussion
The arr2-KO mice have proven to be a valuable animal model
for studying how regulation of the OR can lead to differences in
behavioral responses to the OR agonist morphine. Previously,
we reported that the anitinociceptive properties of morphine are
enhanced in mice lacking arr2 (Bohn et al., 1999). Here we
demonstrate that morphine induces a greater increase in striatal
dopamine release after morphine treatment (Fig. 5), which cor-
relates with the increased conditioned place preference (Fig. 6A)
in the arr2-KO mice compared with the WT mice. These obser-
vations give additional support to the general principle that the
inactivation of components of G-protein-coupled receptor
kinase/arrestin-mediated desensitization mechanisms can lead to
enhanced receptor signaling, and thereby, enhanced behavioral
responses (Bohn et al., 1999, 2002; Gainetdinov et al., 1999a,
2003). However, removal of arr2 actually leads to less enhance-
ment of locomotor activity after morphine (Fig. 1), although
both genotypes experience comparable behavioral sensitization
to this drug (Fig. 3) after repeated administration, indicating that
not all of the effects of morphine are potentiated in the absence of
arr2 and could reflect differential roles of arr2 in the regula-
tion of the receptor in different neuronal populations (Bohn et
al., 2002).
The activation of both opioid and dopamine receptors plays a
critical role in the reinforcing effects of morphine (Koob, 1992;
Shippenberg et al., 1993; Maldonado et al., 1997; Kieffer, 1999;
Elmer et al., 2002). Morphine and cocaine, as well as many other
major drugs of abuse, lead to increased dopamine signaling in
mesolimbic brain structures, such as the nucleus accumbens
(NAc) (Di Chiara and Imperato, 1988; Pontieri et al., 1995;
Shoaib et al., 1995; He and Shippenberg, 2000; Murphy et al.,
Figure 6. In vivo microdialysis after acute cocaine. The effects of cocaine (20 mg/kg, i.p.) and
saline (10 l/g, i.p.) on extracellular DA levels in the striatum of freely moving mice as mea-
sured using in vivo microdialysis. Data are presented as the percentage of the average level of
dopamine measured in at least three samples collected before the drug administration. Analysis
of area under curve values for 2 hr after cocaine treatment (data not shown) revealed a signif-
icant increase in DA in both genotypes compared with the saline treatment of the respective
genotype ( p  0.01; two-tailed Mann–Whitney U test). No significant differences were ob-
served between genotypes after saline (WT, n  5; arr2-KO, n  5) or cocaine (WT, n  5;
KO, n  4; p  0.05; two-tailed Mann–Whitney U test).
Figure 7. Morphine-induced conditioned place preference. Mice were assessed for the time
spent in either the black or white compartment on the preconditioning day. Drug was alterna-
tively paired with either side for both groups of mice as described in Materials and Methods.
After the 6 d conditioning regimen (drug on days 1, 3, and 5; saline on days 2, 4, and 6), the time
spent in each compartment was assessed in the absence of drug or saline (postconditioning). A,
Data are shown as the difference in the time spent in the drug-paired (morphine, 3 mg/kg, s.c.)
compartment on the postconditioning day and the preconditioning day when the data are
analyzed at 10, 15, or 20 min preconditioning and postconditioning times (mean  SEM). The
arr2-KO mice spent more time in the drug-paired side than the WT mice when compared over
all times (for genotype, F(1,11)  5.53, p  0.05; for time, F(2,22)  15.20, p  0.0001). B,
Dose–response curve at 20 min preconditioning and postconditioning times. Morphine pro-
duced a dose-dependent increase in preference for the morphine-paired compartment in both
genotypes; however, when comparing genotypes, the effect was significantly greater in the
arr2-KO mice compared with their WT littermates (for genotype, F(1,41)  6.31, p  0.05; for
dose, F(2,41)  7.05, p  0.01; n  9 per group).
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2001). However, in the case of morphine, stimulation of dopa-
mine pathways is indirect, originating from a disinhibition of
GABAergic cells in dopamine cell body regions (within substan-
tia nigra and the ventral tegmental area), leading to increased
firing, and consequently, increased dopamine release in terminal
regions (within striatum and NAc) (Di Chiara and North, 1992;
Johnson and North, 1992). Morphine, however, can also exert a
direct effect on dopamine dynamics in the NAc (Spanagel et al.,
1992) and exert some effects in a dopamine-independent manner
(Kalivas et al., 1983).
Regardless of the mechanism for increasing dopamine signal-
ing, the activation of the dopaminergic system, particularly in the
mesolimbic system, is an integral part of the initial response to
most major drugs of abuse, including morphine and cocaine, and
therefore was the focus of our behavioral and neurochemical
studies (Di Chiara and Imperato, 1988; Wise and Rompre, 1989;
White and Kalivas, 1998; De Vries and Shippenberg, 2002). Co-
caine is known to act by blocking the monoamine transporters
and thereby preventing reuptake of monoamines, including do-
pamine, which leads to elevated levels of neurotransmitter in the
extracellular space. In our findings, cocaine promotes similar lev-
els of locomotor activity (Fig. 2), behavioral sensitization (Fig. 4),
dopamine response (Fig. 6), and conditioned place preference
(Fig. 8) in both arr2-KO and WT mice, which suggests that the
elimination of arr2 has little effect on the behaviors elicited by
cocaine, which may reflect a less critical role of arr2 in the reg-
ulation of dopaminergic signaling.
It is interesting that, although the arr2-KO mice demon-
strate increased striatal dopamine release and enhanced condi-
tioned place preference with morphine, they do not display en-
hanced locomotor activation. In contrast, the arr2-KO mice
actually display markedly less hyperactivity than their WT con-
trols after each dose of morphine tested (Fig. 1C). To some ex-
tent, this might be explained by the decreased basal levels of ac-
tivity in the arr2-KO mice; however, the magnitude of the
difference after morphine treatment, unlike that observed after
cocaine, is great enough to suggest that mechanisms other than
those responsible for the difference in the basal activity might be
involved. Morphine-induced increases in locomotor behavior
are likely dependent not only on OR-mediated activation of
dopamine signaling but also on other neurotransmitter mecha-
nisms because several neurotransmitter systems can modulate
dopamine-dependent locomotor activation. For example, a sup-
pression of locomotor activation is observed after direct and in-
direct dopamine agonists when the serotonergic system is coac-
tivated (Gainetdinov et al., 1999b, 2001). Morphine has been
shown to elevate serotonergic transmission (Tao and Auerbach,
1994) in addition to elevating dopamine transmission (Di Chiara
and Imperato, 1988). Furthermore, it has been shown that inhi-
bition of the serotonin transporter may counteract morphine
hyperactivity (Sills and Fletcher, 1997; Ise et al., 2001). Therefore,
one potential mechanism may be related to possible alterations in
the OR-mediated regulation of the serotonergic system or in
serotonin receptors per se in the arr2-KO mice, which might
contribute to the reduced locomotor response to morphine even
in the presence of high striatal extracellular dopamine.
Historically, the locomotor response has been considered a
predictor of whether a drug will be reinforcing (Wise and
Bozarth, 1987). Furthermore, locomotor activation and sensiti-
zation have both been used in initial screening for potential alter-
ations in opiate and psychostimulant reinforcement mecha-
nisms. However, the decreased activation observed in the
arr2-KO mice after morphine not only did not correspond to
the higher elevation of dopamine release in these animals but also
contrasted the findings in the conditioned place preference par-
adigm. In fact, enhanced increases in dopamine levels after acute
morphine in the arr2-KO mice correlate best with the enhanced
rewarding properties also observed in these animals in the con-
ditioned place preference procedure (Fig. 7). Our findings sup-
port a growing body of literature documenting that locomotor
responses to morphine do not necessarily correlate with its
dopamine-releasing properties and therefore cannot serve as an
indicator of the reinforcing properties of a drug (Maldonado et
al., 1997; Spielewoy et al., 2000; Murphy et al., 2001; Rouge-Pont
et al., 2002).
For the most part, the differences seen in this study comparing
the WT and arr2-KO mice were only observed when morphine,
but not cocaine, was administered. The removal of arr2 had no
apparent physiological effect in response to cocaine, as evidenced
by the minimal alterations of the behavioral and neurochemical
effects observed in the arr2-KO mice. In addition, the robust
sensitization of locomotor-stimulating effects of both chronic
morphine and cocaine indirectly suggest that dopamine
receptor-mediated signaling may be unchanged in the arr2-KO
mice. To address the question of why removing the arr2 regu-
latory element may not effect all GPCRs, an attractive hypothesis
is that the complement of the other isoform of arrestin,
arrestin-1, is sufficient to regulate the dopamine receptors in the
absence of arr2. It has been shown in transfected cell culture
systems that both D1 and D2 dopamine receptors will interact
with both types of arrestins (Oakley et al., 2000; Kim et al.,
2001). The ability of the complement of arrestin-1 to suffice for
the regulation of most GPCRs may become more apparent as
more agonists are tested in the arr2-KO mice. For example,
treatment with the 2 adrenergic receptor agonist clonidine
does not reveal differences in antinociception between WT
and arr2-KO mice (L. M. Bohn, unpublished observations).
Moreover, these observations highlight how the specificity of
regulation of physiological processes may be established in the
organism.
Together, these finding indicate that the loss of arr2 leads to
increases in morphine-induced striatal dopamine release, intact
Figure 8. Cocaine-induced conditioned place preference. Conditioning was performed as
described in Figure 7A with cocaine (10 mg/kg, i.p.). Data are shown as the difference in the
time spent in the drug-paired compartment on the postconditioning day and the precondition-
ing day when the preconditioning and postconditioning times were set at 10, 15, or 20 min
(mean  SEM). Cocaine (10 mg/kg, i.p.) produced preference for the cocaine-paired compart-
ment in both genotypes that did not differ under any of the conditions (for genotype, F(1,16) 
0.05, p  0.8179; for time, F(2,32)  5.95, p  0.01; n  9 –10 per group).
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locomotor sensitization to morphine and cocaine, as well as en-
hanced conditioned place preference when morphine, but not
cocaine, is the challenging drug. Considering the enhanced
morphine-induced antinociception reported previously in the
arr2-KO mice and its correlation with enhanced OR receptor
signaling, it would appear that the loss of arr2 leads to greater
morphine reinforcement that is related to increases in morphine-
induced dopaminergic activation and not necessarily attributable
to direct alterations in dopaminergic signaling.
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